HomeCompareETNB vs EQR

ETNB vs EQR: Dividend Comparison 2026

ETNB yields 13.48% · EQR yields 5.87%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ETNB wins by $739.00 in total portfolio value
10 years
ETNB
ETNB
● Live price
13.48%
Share price
$14.84
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$48.5K
Annual income
$3,111.66
Full ETNB calculator →
EQR
EQR
● Live price
5.87%
Share price
$59.15
Annual div
$3.47
5Y div CAGR
15.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$47.8K
Annual income
$5,475.61
Full EQR calculator →

Portfolio growth — ETNB vs EQR

📍 ETNB pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodETNBEQR
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ETNB + EQR cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ETNB pays
EQR pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ETNB
Annual income on $10K today (after 15% tax)
$1,145.55/yr
After 10yr DRIP, annual income (after tax)
$2,644.91/yr
EQR
Annual income on $10K today (after 15% tax)
$499.01/yr
After 10yr DRIP, annual income (after tax)
$4,654.27/yr
At 15% tax rate, EQR beats the other by $2,009.36/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ETNB + EQR for your $10,000?

ETNB: 50%EQR: 50%
100% EQR50/50100% ETNB
Portfolio after 10yr
$48.2K
Annual income
$4,293.63/yr
Blended yield
8.92%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EQR right now

ETNB
Analyst Ratings
9
Buy
6
Hold
Consensus: Buy
Price Target
$17.17
+15.7% upside vs current
Range: $12.00 — $25.00
Altman Z
12.5
Piotroski
2/9
EQR
Analyst Ratings
16
Buy
28
Hold
2
Sell
Consensus: Hold
Price Target
$70.35
+18.9% upside vs current
Range: $63.00 — $78.50
Altman Z
1.8
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ETNB buys
0
EQR buys
0
No recent congressional trades found for ETNB or EQR in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricETNBEQR
Forward yield13.48%5.87%
Annual dividend / share$2.00$3.47
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%15.8%
Portfolio after 10y$48.5K$47.8K
Annual income after 10y$3,111.66$5,475.61
Total dividends collected$22.0K$23.0K
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusBuyHold
Analyst price target$17.17$70.35

Year-by-year: ETNB vs EQR ($10,000, DRIP)

YearETNB PortfolioETNB Income/yrEQR PortfolioEQR Income/yrGap
1← crossover$12,048$1,347.71$11,380$679.82+$668.00ETNB
2$14,409$1,517.46$13,014$837.25+$1.4KETNB
3$17,113$1,696.08$14,961$1,036.20+$2.2KETNB
4$20,194$1,882.68$17,297$1,289.22+$2.9KETNB
5$23,684$2,076.25$20,121$1,613.15+$3.6KETNB
6$27,617$2,275.75$23,561$2,030.84+$4.1KETNB
7$32,031$2,480.12$27,783$2,573.54+$4.2KETNB
8$36,961$2,688.28$33,013$3,284.39+$3.9KETNB
9$42,447$2,899.14$39,547$4,223.51+$2.9KETNB
10$48,530$3,111.66$47,791$5,475.61+$739.00ETNB

ETNB vs EQR: Complete Analysis 2026

ETNBStock

89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also intends to develop pegozafermin for the treatment of severe hypertriglyceridemia. 89bio, Inc. was incorporated in 2018 and is headquartered in San Francisco, California.

Full ETNB Calculator →

EQRREIT

Equity Residential is committed to creating communities where people thrive. The Company, a member of the S&P 500, is focused on the acquisition, development and management of residential properties located in and around dynamic cities that attract high quality long-term renters. Equity Residential owns or has investments in 305 properties consisting of 78,568 apartment units, located in Boston, New York, Washington, D.C., Seattle, San Francisco, Southern California and Denver.

Full EQR Calculator →
📬

Get this ETNB vs EQR comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ETNB vs SCHDETNB vs JEPIETNB vs OETNB vs KOETNB vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.